NCT04653818View on ClinicalTrials.gov

HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Hepatocellular CarcinomaHepatitis CNeoplasm RecurrenceTreatment Complication
Interventions
DRUG

Velpatasvir/Sofosbuvir

sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.

Trial Locations (1)

21131

Alexandria University, Faculty of Medicine, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER

NCT04653818 - HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter